Markus Perola

Markus Perola

Auto-generated profile, based on publicly available information

Markus Perola

Faculty of Medicine, Clinical and Molecular Metabolism Research Program (CAMM), University of Helsinki , Helsinki

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2010 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ESElizabeth K Speliotes
Elizabeth K Speliotes
MAMagic
Magic
CWCristen J Willer
Cristen J Willer
SBSonja I Berndt
Sonja I Berndt
KMKeri L Monda
Keri L Monda
OCon behalf of Procardis Consortium
on behalf of Procardis Consortium
Ruth Loos and colleagues report results of a large genome-wide association study for body mass index. They identify 18 new loci associated with this trait, some of which map near key hypothalamic regulators of energy balance. Obesity is globally prevalent and highly heritable, but its underlying genetic factors remain largely elusive. To identify genetic loci for obesity susceptibility, we examined associations between body mass index and ∼2.8 million SNPs in up to 123,865 individuals with targeted follow up of 42 SNPs in up to 125,931 additional individuals. We confirmed 14 known obesity susceptibility loci and identified 18 new loci associated with body mass index (P < 5 × 10−8), one of which includes a copy number variant near GPRC5B. Some loci (at MC4R, POMC, SH2B1 and BDNF) map near key hypothalamic regulators of energy balance, and one of these loci is near GIPR, an incretin receptor. Furthermore, genes in other newly associated loci may provide new insights into human body weight regulation.

13 May 2012 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
AMAlisa K Manning
Alisa K Manning
MHMarie-France Hivert
Marie-France Hivert
RSRobert A Scott
Robert A Scott
JGJonna L Grimsby
Jonna L Grimsby
NBNabila Bouatia-Naji
Nabila Bouatia-Naji
CLClaudia Langenberg
Claudia Langenberg

25 April 2010 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TCThe ENGAGE Consortium
The ENGAGE Consortium
TTThorgeir E Thorgeirsson
Thorgeir E Thorgeirsson
DGDaniel F Gudbjartsson
Daniel F Gudbjartsson
ISIda Surakka
Ida Surakka
JVJacqueline M Vink
Jacqueline M Vink
KSKari Stefansson
Kari Stefansson

1 February 2014 in BMC Endocrine Disorders
Verified
Journal Article
Open access
PDF file
JVJana V van Vliet-Ostaptchouk
Jana V van Vliet-Ostaptchouk
MNMarja-Liisa Nuotio
Marja-Liisa Nuotio
SSSandra N Slagter
Sandra N Slagter
DDDany Doiron
Dany Doiron
KFKrista Fischer
Krista Fischer
BWBruce H.R. Wolffenbuttel
Bruce H.R. Wolffenbuttel
Not all obese subjects have an adverse metabolic profile predisposing them to developing type 2 diabetes or cardiovascular disease. The BioSHaRE-EU Healthy Obese Project aims to gain insights into the consequences of (healthy) obesity using data on risk factors and phenotypes across several large-scale cohort studies. Aim of this study was to describe the prevalence of obesity, metabolic syndrome (MetS) and metabolically healthy obesity (MHO) in ten participating studies. Ten different cohorts in seven countries were combined, using data transformed into a harmonized format. All participants were of European origin, with age 18–80 years. They had participated in a clinical examination for anthropometric and blood pressure measurements. Blood samples had been drawn for analysis of lipids and glucose. Presence of MetS was assessed in those with obesity (BMI ≥ 30 kg/m2) based on the 2001 NCEP ATP III criteria, as well as an adapted set of less strict criteria. MHO was defined as obesity, having none of the MetS components, and no previous diagnosis of cardiovascular disease. Data for 163,517 individuals were available; 17% were obese (11,465 men and 16,612 women). The prevalence of obesity varied from 11.6% in the Italian CHRIS cohort to 26.3% in the German KORA cohort. The age-standardized percentage of obese subjects with MetS ranged in women from 24% in CHRIS to 65% in the Finnish Health2000 cohort, and in men from 43% in CHRIS to 78% in the Finnish DILGOM cohort, with elevated blood pressure the most frequently occurring factor contributing to the prevalence of the metabolic syndrome. The age-standardized prevalence of MHO varied in women from 7% in Health2000 to 28% in NCDS, and in men from 2% in DILGOM to 19% in CHRIS. MHO was more prevalent in women than in men, and decreased with age in both sexes. Through a rigorous harmonization process, the BioSHaRE-EU consortium was able to compare key characteristics defining the metabolically healthy obese phenotype across ten cohort studies. There is considerable variability in the prevalence of healthy obesity across the different European populations studied, even when unified criteria were used to classify this phenotype.

11 October 2009 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
NSNicole Soranzo
Nicole Soranzo
TSTim D Spector
Tim D Spector
MMMassimo Mangino
Massimo Mangino
BKBrigitte Kühnel
Brigitte Kühnel
ARAugusto Rendon
Augusto Rendon
CGChristian Gieger
Christian Gieger

1 October 2010 in The Lancet
Verified
Journal Article
Open access
SRSamuli Ripatti
Samuli Ripatti
ETEmmi Tikkanen
Emmi Tikkanen
MOMarju Orho-Melander
Marju Orho-Melander
AHAki S Havulinna
Aki S Havulinna
KSKaisa Silander
Kaisa Silander
SKSekar Kathiresan
Sekar Kathiresan
Comparison of patients with coronary heart disease and controls in genome-wide association studies has revealed several single nucleotide polymorphisms (SNPs) associated with coronary heart disease. We aimed to establish the external validity of these findings and to obtain more precise risk estimates using a prospective cohort design. We tested 13 recently discovered SNPs for association with coronary heart disease in a case-control design including participants differing from those in the discovery samples (3829 participants with prevalent coronary heart disease and 48,897 controls free of the disease) and a prospective cohort design including 30,725 participants free of cardiovascular disease from Finland and Sweden. We modelled the 13 SNPs as a multilocus genetic risk score and used Cox proportional hazards models to estimate the association of genetic risk score with incident coronary heart disease. For case-control analyses we analysed associations between individual SNPs and quintiles of genetic risk score using logistic regression. In prospective cohort analyses, 1264 participants had a first coronary heart disease event during a median 10·7 years' follow-up (IQR 6·7-13·6). Genetic risk score was associated with a first coronary heart disease event. When compared with the bottom quintile of genetic risk score, participants in the top quintile were at 1·66-times increased risk of coronary heart disease in a model adjusting for traditional risk factors (95% CI 1·35-2·04, p value for linear trend=7·3×10(-10)). Adjustment for family history did not change these estimates. Genetic risk score did not improve C index over traditional risk factors and family history (p=0·19), nor did it have a significant effect on net reclassification improvement (2·2%, p=0·18); however, it did have a small effect on integrated discrimination index (0·004, p=0·0006). Results of the case-control analyses were similar to those of the prospective cohort analyses. Using a genetic risk score based on 13 SNPs associated with coronary heart disease, we can identify the 20% of individuals of European ancestry who are at roughly 70% increased risk of a first coronary heart disease event. The potential clinical use of this panel of SNPs remains to be defined. The Wellcome Trust; Academy of Finland Center of Excellence for Complex Disease Genetics; US National Institutes of Health; the Donovan Family Foundation.